Anti-VSIR/VISTA Antibody (SG7)
Based on 1 publication(s) in Google Scholar
Anti-VSIR/VISTA Antibody (SG7) is an antibody targeting VISTA, with a Kd of 0.14 nM for human VISTA and 1 nM for mouse VISTA. Anti-VSIR/VISTA Antibody (SG7) blocks the function of VISTA, prevents VISTA from binding to T cells, restores suppressed T cell activation, and blocks the interactions between VISTA and PSGL-1 as well as VSIG3. Anti-VSIR/VISTA Antibody (SG7) slows tumor growth, reduces PMN-MDSCs, and increases the numbers of CD4+ and CD8+ T cells in the tumor microenvironment. Anti-VSIR/VISTA Antibody (SG7) can be used in studies related to melanoma, colon cancer, and breast cancer.
For research use only. We do not sell to patients.
- Purity : 98.07%
- Molecular Weight:144.52 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Anti-VSIR/VISTA Antibody (SG7)
More
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
In Vitro
Anti-VSIR/VISTA Antibody (SG7) completely blocks the binding of mouse VISTA-Fc to activated C57BL/6 mouse T cells at pH 6.0[1].
Anti-VSIR/VISTA Antibody (SG7) completely blocks the binding of human VISTA-Fc to activated human CD4+/CD8+ T cells at pH 6.0[1].
Anti-VSIR/VISTA Antibody (SG7) (1 µM; 48 h) restores the activation level of human Jurkat NFAT reporter T cells to the level observed with anti-CD3 treatment alone by inhibiting the VISTA signaling pathway[1].
Anti-VSIR/VISTA Antibody (SG7) (2 h) blocks the interaction between human VISTA-Fc and human PSGL-1-Fc at pH 6.0[1].
Anti-VSIR/VISTA Antibody (SG7) (2 h) blocks the interaction between human VISTA-Fc and human VSIG3-Fc at pH 6.0[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Anti-VSIR/VISTA Antibody (SG7) (dead Fc) (30 mg/kg; i.p.; twice weekly; 3 total injections) significantly inhibits tumor growth of MC38 colon cancer cells in female C57BL/6J mice[1].
Anti-VSIR/VISTA Antibody (SG7) (active Fc and dead Fc) (30 mg/kg; i.p.; twice weekly; 3 injections total) significantly inhibits the tumor growth of 4T1 breast cancer in female BALB/cJ mice. Among them, SG7 (active Fc) can also reshape the tumor microenvironment by reducing PMN-MDSCs and increasing T cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (female, 8-10 weeks old, B16F10 melanoma cells injected into right flank)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; twice weekly; 2 weeks
-
Result:Significantly inhibited tumor growth compared to PBS-treated mice.
Reduced mean tumor volume to ~1000 mm3 by day 21, compared to ~1600 mm3 in PBS-treated mice.
-
Animal Model:C57BL/6J (female, 8-10 weeks old, MC38 colon carcinoma cells injected into right flank)[1]
-
Dosage:30 mg/kg
-
Administration:i.p.; twice weekly; 3 injections
-
Result:Significantly reduced tumor growth compared to PBS-treated mice.
Reduced mean tumor volume to ~600 mm3 by day 17, compared to ~850 mm3 in PBS-treated mice.
Showed greater efficacy when combined with anti-PD1, with a mean tumor volume of ~250 mm3 by day 17.
-
Animal Model:BALB/cJ (female, 8-10 weeks old, 4T1 breast cancer cells injected into right flank)[1]
-
Dosage:30 mg/kg (active Fc); 30 mg/kg (dead Fc)
-
Administration:i.p.; twice weekly; 3 injections
-
Result:Caused a minor but significant decrease in tumor volume compared to PBS-treated mice by day 17, with mean tumor volume ~220 mm3 for both SG7 groups, compared to ~320 mm3 in PBS-treated mice.
Significantly decreased the percentage of PMN-MDSCs and significantly increased the percentage of CD4+ and CD8+ T cells in tumor infiltrates (SG7 active Fc group only).
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Human VISTA Protein, hFc Tag can bind Anti-VSIR/VISTA Antibody (SG7). The EC50 for this effect is 119.1 ng/mL.
Chemical Information
-
Appearance Liquid
-
Molecular Weight 144.52 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-VSIR/VISTA Antibody (SG7)]
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cancer Cell
IGSF11-VISTA is a critical and targetable immune checkpoint axis in diffuse midline glioma. [Abstract]2026 Jan 22:S1535-6108(25)00554-9. PMID: 41576930
Purity & Documentation
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-VSIR/VISTA Antibody (SG7) Related Classifications
HY-P991447 Related Classifications
Powered by Bioz